• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 114
  • 90
  • 9
  • 9
  • 9
  • 8
  • 8
  • 8
  • 6
  • 3
  • 3
  • 3
  • 2
  • 1
  • 1
  • Tagged with
  • 321
  • 76
  • 70
  • 63
  • 40
  • 33
  • 30
  • 28
  • 23
  • 22
  • 22
  • 21
  • 19
  • 18
  • 18
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
91

Avaliação da eficácia da 5-Azacitidina e SAHA nas linhagens de hemangiossarcoma canino / Visceral hemangiosarcoma in dogs: a retrospective study of 42 cases (2005-2014)

Karen Batschinski 15 December 2017 (has links)
O hemangiossarcoma é uma neoplasia maligna de origem endotelial vascular de ocorrência comum em cães. Nessa espécie, o órgão primário mais acometido é o baço. O hemangiossarcoma de partes moles em cães é caracterizado por ter um comportamento biológico muito agressivo e metástases, principalmente para o pulmão e fígado, são frequentes e ocorrem de maneira rápida no início do curso da doença. O óbito ocorre na maioria dos casos devido a hemorragia interna aguda secundária à ruptura do tumor e/ou devido ao processo metastástico. A cirurgia continua a ser o principal método de tratamento para quase todos os cães com hemangiossarcoma, mas a quimioterapia adjuvante é indicada em razão do alto índice metastático e do prognóstico ruim associado com o procedimento cirúrgico sozinho. Um estudo retrospectivo foi realizado para determinar o tempo de sobrevida e potenciais fatores de risco em cães diagnosticados com hemangiossarcoma visceral. Prontuários de 42 cães foram revisados. Dados como idade e peso no momento do diagnóstico, raça, sexo, localização do tumor, estágio clínico da doença, tipo de tratamento, e tempo mediano de sobrevida foram analisados. Vinte e três cães foram tratados apenas com cirurgia, enquanto que 19 cães foram tratados com cirurgia e quimioterapia adjuvante. Houve diferença estatística na sobrevida dos cães tratados com cirurgia e Doxorrubicina (274 dias) em comparação com cães tratados apenas com cirurgia (66 dias). Cães com hemangiossarcoma esplênico tiveram um tempo mediano de sobrevida mais longo do que os cães com hemangiossarcoma localizados em outros sítios primários e com metástase (274 versus 117 versus 38 dias, respectivamente, p = 0,013). O tempo mediano global de sobrevida para esses 42 cães foi de 237 dias, e a taxa de sobrevida de um ano foi estimada em 26,32%. Conclui-se que a localização primária do hemangiossarcoma teve associação com o prognóstico e que o uso da Doxorrubicina após o tratamento cirúrgico aumentou a sobrevida dos cães diagnosticados com essa doença. Neste estudo, o estadiamento clínico dos cães não influenciou o prognóstico / Hemangiosarcoma is a very common canine neoplasm of vascular endothelial origin. In the dog, the most frequent primary site for hemangiosarcoma is the spleen. Typically, canine hemangiosarcoma has a very aggressive biologic behavior with metastases, especially to lung and liver, occurring early in the course of the disease. In the majority of cases, death is related to acute hemoabdomen secondary to tumor rupture and/or metastases. Surgery remains the main method of treatment for most dogs with this type o cancer, but adjuvant chemotherapy is highly recommended due to the high risk of metastasis and the poor outcome associated with surgery alone. A retrospective study was performed to determine survival times and potential risk factors in dogs diagnosed with visceral hemangiosarcoma. Medical records of 42 dogs were reviewed. Age and baseline weight at the time of diagnosis, breed, sex, tumor location, clinical stage of the disease, treatment type and median survival time were evaluated. Twenty-three dogs were treated with surgery alone, while 19 dogs were treated with surgery and adjuvant chemotherapy. There was significant difference in survival between dogs treated with surgery alone (66 days) and with surgery followed by Doxorubicin (274 days). Dogs with splenic hemangiosarcoma had a longer median survival time than dogs with hemangiosarcoma of other sites, and with metastasis (274 versus 117 versus 38 days, respectively, p = 0,013). The overall median survival time for these 42 dogs was 237 days, and the one-year survival rate was estimated to be 26.32%. In conclusion, primary tumor location was associated with prognosis and the addition of doxorubicin after surgery did improve survival. In this study, clinical stage had no association with prognosis
92

Desenvolvimento de formulações iontoforéticas semi-sólidas para o tratamento de tumores cutâneos: estudo \'in vitro\' em cultura de células tumorais / Development of semi-solid iontophoretic formulations for treatment of cutaneous tumor: in vitro studies on tumor cell culture.

Stephânia Fleury Taveira 23 March 2007 (has links)
O objetivo deste trabalho foi estudar a permeação iontoforética da Doxorrubicina (DOX) em formulações semi-sólidas e testar a citotoxicidade destas formulações em cultura de células de melanoma com e sem a aplicação de corrente elétrica de baixa intensidade. O estudo de liberação da DOX das formulações (gel de Hidroxietilcelulose ? HEC, gel de quitosana e solução aquosa) mostrou que o gel de quitosana possuiu uma velocidade de liberação quase três vezes maior do que nas demais formulações. Os estudos de permeação passiva mostraram que o fármaco não atravessa a pele em quantidades detectáveis. No entanto, a iontoforese contribui significativamente não só na permeação da DOX, mas também na sua retenção cutânea. O gel de HEC foi o que levou a uma maior retenção cutânea do fármaco em comparação com as demais formulações. Nos estudos de citotoxicidade realizados em células de melanoma de camundongos, verificou-se que as formulações contendo DOX possuíram citotoxicidade maior comparadas ao controle (solução de DOX). Isso significa que os componentes de cada formulação contribuem no poder de citotoxicidade contra as células de melanoma. A solução de monoleína 5% em propilenoglicol apresentou maior atividade citotóxica dentre todas as formulações estudadas. Seus componentes, monoleína e propilenoglicol contribuem sinergicamente para sua atividade citotóxica, a qual é de aproximadamente 90% quando a concentração de DOX é de 20 ng/mL. Enquanto que em solução de DOX sua citotoxicidade é de aproximadamente 34% na mesma concentração. Foi feita a padronização dos estudos de aplicação de corrente elétrica em cultura de células, quanto a placa de cultura, número de células, volume do meio de cultura e ponte salina (utilizada para a passagem da corrente para o meio de cultura). A aplicação de 0,1 a 0,5 mA/cm2 de corrente elétrica não causou morte significativa para as células de melanoma quando aplicada por um período de 10 a 60 minutos. A citotoxicidade das formulações com e sem aplicação de corrente elétrica por 10 minutos não apresentaram diferença significativa. Porém, a aplicação de 20 minutos de corrente elétrica aumentou significativamente a citotoxicidade da DOX em solução aquosa. Conclui-se, resumidamente, que a aplicação de corrente elétrica de baixa intensidade aumentou a penetração da DOX através da pele e auxiliou a entrada do fármaco nas células tumorais, quando esta é dissolvida em solução aquosa. / The aim of this work was to study the iontophoretic delivery of Doxorubicin (DOX) dispersed in semi-solid formulations and test its citotoxicity activity on melanoma cell lines, with or without the application of a low intensity electrical current. The release study of DOX from the formulations (hydroxyethylcellulose ? HEC, chitosan gel and aqueous solution) showed that chitosan gel increased almost 3 times the diffusion coefficient of the drug when compared to a water solution. Passive permeation studies showed that the drug does not cross the skin in detected amounts. However, iontophoresis of DOX increased significantly not only the permeation but also the skin retention of the drug. HEC gel improved DOX skin retention when compared to other formulations. Cytotoxicity studies, performed in rat melanoma cell culture indicated that formulations containing DOX have high citotoxicity compared to the control (DOX solution). These results means that the components of the formulations probably contribute to melanoma cells death. Monoolein 5% solution in propileneglicol showed high citotoxicity compared to the other formulations. Its components act sinergically and produce a great citotoxicity: approximately 90% when the concentration of DOX is 20 ng/mL, whereas in DOX solution its citotoxicity is approximately 34% on this concentration. Standardization of the electrical current studies has been made as matter as the culture plate, number of cells, volume of culture medium and agar bridge (used to pass electrical current for the culture medium). The application of 0,1 to 0,5 mA/cm2 of electrical current during 10 to 60 minutes did not kill melanoma cell lines significantly. The cytotoxicity of DOX incorporated in water and semi-solid formulations are not statistical different in the presence or not of an electrical current for 10 minutes. However, 20 minutes of an electrical current raised significantly the citotoxicity effects of DOX in aqueous solution. In summary, the application of low intensity electrical current increases the penetration of DOX through the skin and helps the drug to enter into the tumor cells, when dispersed in water solution
93

Enhancing Cardiomyocyte Survival in Drug Induced Cardiac Injury

Maharsy, Wael January 2012 (has links)
Cardiotoxicity associated with many cancer drugs is a critical issue facing physicians these days and a huge hurdle that must be overcome for a side effects-free cancer therapy. Survival of cardiac myocytes is compromised upon the exposure to certain chemotherapeutic drugs. Unfortunately, the mechanisms implicated in cardiac toxicity and the pathways governing myocyte survival are poorly understood. The following thesis addresses the mechanisms underlying the cardiotoxicity of two anticancer drugs, doxorubicin (DOX) and Imatinib mesylate (Gleevec). Transcription factor GATA-4, has recently emerged as an indispensable factor in the adult heart adaptive response and cardiomyocyte survival. Therefore, the specific aim of this project was to determine the role of GATA-4, its upstream regulators, as well as partners in survival. A combination of cell and molecular techniques done on in vivo, and ex vivo models were utilized to tackle these issues. In this study, we confirmed the cardiotoxicity of the anticancer drug, Imatinib mesylate and found to be age dependent. GATA-4, already known to be implicated in DOX-induced toxicity, was confirmed as an Imatinib target. At the molecular level, we identified IGF-1 and AKT as upstream regulators of GATA-4. Moreover, we confirmed ZFP260 (PEX-1), a key regulator of the cardiac hypertrophic response, as a GATA-4 collaborator in common prosurvival pathways. Collectively, these results provide new insights on the mechanisms underlying drug-induced cardiotoxicity and raise the exciting possibility that cancer drugs are negatively affecting the same prosurvival pathway(s), in which GATA-4 is a critical component. Therapeutic interventions aimed at enhancing GATA-4 activity may be interesting to consider in the context of treatments with anticancer drugs.
94

Doxorubicin-Immersed Skeletal Muscle Grafts Promote Peripheral Nerve Regeneration Across a 10‐mm Defect in the Rat Sciatic Nerve / ドキソルビシン浸透前処置した筋組織グラフトはラット坐骨神経10mm欠損モデルにて神経再生を促進する

Takeuchi, Hisataka 23 March 2020 (has links)
京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第22315号 / 医博第4556号 / 新制||医||1040(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 井上 治久, 教授 伊佐 正, 教授 妻木 範行 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM
95

Vliv cytochromů P450 na metabolismus protinádorových léčiv vázaných v apoferritinové nanočástici / Effect of cytochromes P450 on metabolism of anticancer drugs bound into apoferritin nanoparticle

Wilhelm, Marek January 2020 (has links)
Tumour-related diseases are the second most common cause of death in the Czech Republic, right after cardiovascular diseases. Nanomedicine - a novel scientific discipline - shows captivating potential in anticancer treatment with help of so called nanotranporters - nanoparticles capable of transporting other molecules. Encapsulation of a cytostatic drug into a nanoparticle improves its pharmacokinetical and pharmacodynamical properties which helps to reduce adverse side effects on non-tumour healthy tissue. In the scope of this diploma thesis apoferritin - apo-form of ferritin - was studied, since this nanotransporter shows promise for clinical use in anticancer treatment. Effect of hepatic microsomes from premedicated and control rats on biotransformation of doxorubicin cytostatic (Dox) in free and apoferritin nanoparticle-bound forms was investigated at pH 7,4. Over the course of biotransformation two types of metabolites - M1 and M2 - were observed. Regardless of the employed inductor all studied microsomes have exhibited similar metabolism of free doxorubicin and its apoferritin encapsulated form (ApoDox). Our results also imply that doxorubicin can be metabolically processed by rat hepatic microsomes in both free and ApoDox form with similar efficiency. We have also studied biotransformation...
96

Bnip3 Mediates Doxorubicin-Induced Cardiomyocyte Pyroptosis via Caspase-3/GSDME

Zheng, Xinbin, Zhong, Ting, Ma, Yeshuo, Wan, Xiaoya, Qin, Anna, Yao, Bifeng, Zou, Huajiao, Song, Yan, Yin, Deling 01 February 2020 (has links)
Aims: This study was aimed to investigate the role of GSDME-mediated pyroptosis in cardiac injury induced by Doxorubicin (DOX), and to evaluate the role of BH3-only protein Bcl-2/adenovirus E1B 19-kDa-interacting protein 3 (Bnip3) in regulation of DOX-induced pyroptosis. Main methods: HL-1 cardiomyocytes and C57BL/6J mice were treated by DOX to establish DOX-induced cardiotoxicity in vitro and in vivo models, respectively. Cell transfection was applied to regulate the expression of caspase-3, GSDME and Bnip3. Western blot was used for measuring expression of protein level. LDH-cytotoxicity assay was used to detect the LDH release. The Flow cytometry analysis was used to detect the cell death. Echocardiography was used to determine the cardiac function. HE staining was used for observing pathological feature of heart tissues. Key findings: Our results showed that GSDME-mediated pyroptosis was involved in DOX-induced cardiotoxicity in vivo. We showed that HL-1 cardiomyocytes exposed to DOX exhibited morphological features of pyroptosis in vitro. We also showed that DOX induced activation of caspase-3 and eventually triggered GSDME-dependent pyroptosis, which was reduced by the silence or inhibitor of caspase-3. We further showed that knockdown of GSDME inhibited DOX-induced cardiomyocyte pyroptosis in vitro. Finally, DOX increased the expression of Bnip3, whereas silencing of Bnip3 blunted cardiomyocyte pyroptosis induced by DOX, which was regulated through caspase-3 activation and GSDME cleavage. Significance: Our findings revealed a novel pathway that cardiomyocyte pyroptosis is regulated through Bnip3-caspase-3-GSDME pathway following DOX treatment, suggesting that Bnip3-dependent pyroptosis may offer a novel therapeutic strategy to reduce cardiotoxicity induced by DOX.
97

Transplantation Of Pluripotent Stem Cells Confers Cardiac Protection In Dox-induced Heart Failure Through Notch-1 Pathway

Merino-Chavez, Hilda 01 January 2012 (has links)
Doxorubicin (DOX) is the antineoplastic drug of preference used to treat a wide variety of malignancies, with high survival rates among treated patients. However, the benefits of this drug have become less appealing due to the side effects that occur such as DOX-induced cardiomyopathy (DIC) and an increased risk of myocardial infarction (MI). Therefore, there is an urgent need to explore the therapeutic options to treat DIC. In this context, adult stem cells have been used as a source to reduce cardiomyocyte apoptosis in DIC; however, the effects of transplanted embryonic stem (ES) cells and induced pluripotent stem (iPS) cells in DIC post MI are unknown. As a result, we wanted to understand how transplanted ES and iPS cells and the factors released by them inhibit apoptosis and improve cardiac function in DIC post MI. C57BL/6 mice were divided into five groups: Sham, DOX-MI, DOX-MI+cell culture (CC) media, DOX-MI+ES cells, and DOX-MI+iPS cells. Mice were treated with DOX (12 mg/kg, cumulative dose) followed by left coronary artery ligation to induce MI. ES or iPS cells (5 x 104 ) were delivered into the peri-infarct region. At day 14 post-MI, echocardiography was performed, mice sacrificed, and hearts harvested for further analyses. To investigate if protective effects are provided by factors released from ES and iPS cells in DIC, we performed in vitro studies using condition media (CM) obtained from ES or iPS cells to treat DOX-induced cardiotoxicity in H9c2 cells. Our data reveal that apoptosis was significantly inhibited in the ES and iPS cell transplanted hearts as well as ESCM and iPSCM treated cells compared with the untreated controls. Furthermore, a significant increase in levels of Notch-1, Hes1, and pAkt survival protein were observed. Decreased levels of PTEN, a negative regulator of Akt pathway, along with improved iv heart function were also observed in the stem cell transplanted groups. In conclusion, our data show that transplantation of ES and iPS cells blunt DOX-induced apoptosis in vivo, which is associated with improved cardiac function. Moreover, decreased apoptosis in both in vitro and in vivo models is mediated by the Notch pathway.
98

MULTIFUNCTIONAL SCAFFOLDS FOR DRUG-DELIVERY THERAPIES

Borges, Thiago FCC 27 January 2016 (has links)
No description available.
99

TAILORING DRUG-CARRIER INTERACTIONS IN POLY(SIALIC ACID) MICELLES FOR USE AS CANCER THERAPEUTIC CARRIERS

Pawlish, Gerald Joseph January 2018 (has links)
Although great progress has been made, cancer still remains one of the most prevalent maladies plaguing mankind. New treatment methodologies using nanoparticles have come to the forefront by allowing for enhanced delivery of therapeutics to the tumor site. The design of the nanoparticle should allow for long circulation times, tumor-specific targeting and efficient release at the site of action. This requires that both the external shell and internal core of the nanoparticle be carefully selected to meet the maximal criteria of each of these steps. Poly(sialic acid) (PSA), a naturally occurring polysaccharide, meets all of the benchmarks of an effective exterior coating yet remains relatively unexplored in the field of drug delivery. Due to stealth properties, natural tumor targeting ability, and inherent pH-responsive elements, PSA has frequently been viewed as a “next-generation” surface coating. Just as important, the internal composition of the carrier should aid in effective drug loading but also rapid release. The selection of the core containing groups as well as therapeutic should be maximized in order to customize the carrier to drug. Here, we have developed PSA micelles composed of various internal groups selected to maximize drug loading and facilitate release. Loading of the chemotherapeutic doxorubicin was optimized through variations in non-covalent bonding forces between drug and carrier. Furthermore, PSA micelles composed of internal pH-responsive groups of varying hydrophobicity were also developed to tailor micelle swelling points at conditions analogous towards those found upon cellular uptake. Both of these were effective delivery platforms towards MCF-7 human breast adenocarcinoma cells. / Bioengineering
100

EPIGENETIC MECHANISMS REGULATING MIXED LINEAGE LEUKEMIA AMPLIFICATIONS AND REARRANGEMENTS

Gray, Zachary 05 1900 (has links)
MLL/KMT2A amplifications and translocations are prevalent in infant, adult and therapy-induced leukemia. However, the molecular contributor(s) to these alterations are unclear. Here we demonstrate that histone H3 lysine 9 mono- and di-methylation (H3K9me1/2) balance at the MLL/KMT2A locus regulates these amplifications and rearrangements. This balance is controlled by the cross-talk between lysine demethylase KDM3B and methyltransferase G9a/EHMT2. KDM3B depletion increases H3K9me1/2 levels and reduces CTCF occupancy at the MLL/KMT2A locus, and in turn, promotes amplification and rearrangements. Depleting CTCF is also sufficient to generate these focal alterations. Furthermore, the chemotherapy Doxorubicin (Dox), which associates with therapy-induced leukemia and promotes MLL/KMT2A amplifications and rearrangements, suppresses KDM3B and CTCF protein levels. KDM3B and CTCF overexpression rescues Dox-induced MLL/KMT2A alterations. G9a inhibition in human cells or mice also suppresses MLL/KMT2A events accompanying Dox treatment. Therefore, MLL/KMT2A amplifications and rearrangements are controlled by epigenetic regulators that are tractable drug targets, which has clinical implications. The data presented in this thesis were published in Cell in 2023. / Biomedical Sciences

Page generated in 0.1518 seconds